View Article

Abstract

Drug-free implantable vagus nerve stimulation (VNS) devices represent a promising neuromodulation technology for managing chronic and treatment-resistant disorders. These implantable systems deliver controlled electrical impulses to the vagus nerve, providing therapeutic effects without long-term drug use. VNS is an approved treatment for drug-resistant epilepsy and treatment-resistant depression, and recent innovations have extended its application to stroke rehabilitation, heart failure, and autoimmune disorders. This review summarizes the structure, mechanism, manufacturers, clinical applications, advantages, limitations, and future directions of drug-free implantable VNS devices. Continuous developments in bioelectronic medicine and closed-loop systems are expected to broaden their clinical utility and improve patient outcomes.

Keywords

Vagus nerve stimulation, Implantable device, Neuromodulation, Drug-free therapy, Bioelectronic medicine, Epilepsy, Depression, Stroke rehabilitation

Introduction

  • Vagus nerve stimulator (VNS) is an drug free implantable device.
  • Acts like a ‘pacemaker for the brain’.
  • Implantable Vagus nerve stimulation device is a pulse generator, implanted under the skin to stimulate the vagus nerve.
  • The vagus nerve stimulation (VNS) device is a bioelectronic implant that helps control brain activity by sending mild electrical signals to the vagus nerve.
  • It is mainly used to treat epilepsy (seizures) and depression when medicines don’t work.

WHEN IT WAS INVENTED & IT’S HISTORY                        

19th century:

The vagus nerve was first studied for its role in heart rate, digestion, and the autonomic nervous system. Researchers found that stimulating the vagus could slow the heart and affect respiration.

1930s–1950s:

Experiments in animals showed that electrical stimulation of the vagus could influence brain activity, suggesting potential therapeutic use in neurological disorders.

Origins of Vagus Nerve Stimulation Therapy

1980s:

Researchers began exploring the vagus nerve as a therapeutic target for epilepsy.

In 1985, Jacob Zabara, a researcher in the U.S., demonstrated that intermittent vagus nerve stimulation reduced seizure activity in dogs.

Zabara founded Cyberonics, Inc. in 1987 to develop implantable VNS devices.

First Human Use and FDA Approval

1988–1990:

The first human clinical trials of VNS for refractory epilepsy were conducted. The results showed reduced seizure frequency in some patients.

1994:

The VNS Therapy System (Cyberonics) received CE Mark approval in Europe for epilepsy.

1997:  

The U.S. FDA approved VNS therapy as an adjunctive treatment for refractory epilepsy in adults and children over 12 years old.

2005:

The FDA approved VNS for treatment-resistant depression (TRD) after evidence showed mood improvement in some patients unresponsive to medication.

2010s:

Research expanded into heart failure, anxiety disorders, migraine, cluster headaches, and inflammatory diseases (e.g., rheumatoid arthritis).

Table No1: based on the discovery of vagus nerve stimulation device

WHAT IS VAGUS NERVE

The vagus nerve (also known as the 10 cranial nerve, or cranial nerve X) is the longest and one of the most complex nerves in the autonomic nervous system.

The part of your nervous system that controls Involuntary actions like heart rate, digestion, and breathing, moods, seizure.

Connects brain to heart, lungs, stomach, intestines.

Anatomy and Pathway

Origin:

Begins in the brainstem, specifically in the medulla oblongata.

Pathway:

Travels down the neck, through the chest, and into the abdomen.

Connections:

It sends fibers to several organs:

  • Heart
  • Lungs
  • Stomach and intestines
  • Liver
  • Spleen
  • Voice box (larynx) and throat (pharynx)

Table No 2:  Functions of Vagus Nerve

Why It’s Important in Medicine

  • Epilepsy (reducing seizure frequency)
  • Depression and anxiety
  • Inflammatory diseases (like rheumatoid arthritis)
  • Heart conditions
  • Headaches and migraines

WHAT IS VAGUS NERVE STIMULATION DEVICE

A vagus nerve stimulation (VNS) device is a medical device designed to stimulate the vagus nerve — a long cranial nerve that runs from the brainstem through the neck and into the chest and abdomen. The vagus nerve helps regulate many vital functions, including heart rate, digestion, and mood.

  • Small electronic device implanted under the skin of chest.
  • Sends regular electrical impulses to the vagus nerve.
  • Helps reduce abnormal brain activity and balance functions.

Figure No 1: Diagrammatic representation of VNS (reference in 13)

Types of VNS Devices

  1. Implantable VNS (traditional):
      1. Surgically implanted under the skin.
      2. Battery-powered pulse generator.
      3. Controlled by a doctor with an external programmer.
  2. Non-invasive (transcutaneous) VNS:
  1. Handheld or ear-worn devices that stimulate the vagus nerve through the skin.
  2. No surgery needed
  3. Examples: gammaCore, NEMOS, etc.  

IMPLANTABLE VNS

A vagus nerve stimulation (VNS) device is a medical device designed to stimulate the vagus nerve — a long cranial nerve that runs from the brainstem through the neck and into the chest and abdomen. The vagus nerve helps regulate many vital functions, including heart rate, digestion, and mood.

PARTS OF VAGUS NERVE STIMULATION DEVISE

  1. Pulse Generator
  2. Leads(Wires)
  3. Programmer System

PULES GENERATOR (Implantable Stimulator)

  • A small, battery-powered device (like a pacemaker).
  • Implanted under the skin in the upper chest.
  • Generates electrical pulses. (battery+ computer)
  • A small, round device—about the size of a silver dollar (2–3 cm in diameter).
  • Contains a battery and an electronic circuit that generates electrical pulses.

Main Components & Materials of an Implantable Pulse Generator

Titanium or Biocompatible Metal Casing

    • The outer shell of the generator is usually made from titanium (a metal that is biocompatible, corrosion-resistant, and non-reactive with body tissues).
    • The casing protects the internal electronics from body fluids and mechanical damage.

 Electronic Circuitry (Pulse Generation Unit)

  • A microprocessor and custom circuitry inside generate precisely timed electrical pulses.
  • The system allows doctors to program parameters such as
  1. Pulse amplitude (intensity)
  2. Pulse width
  3. Frequency
  4. On/off timing cycles

Battery (Power Source)

  • A lithium-based battery, typically lithium-carbon monofluoride (Li-CFx) or lithium-manganese dioxide (Li-MnO?), is used for long life and stability.
  • The battery life is usually 5 to 10 years, depending on stimulation settings and frequency.

Telemetry Coil / Communication System

  • Embedded coil allows wireless communication between the implanted device and an external programmer.
  • Clinicians use this to adjust settings or check device status without surgery.

Connector Port

  • The top part of the generator includes a connector where the lead wire attaches.
  • The lead carries the stimulation pulses from the generator to the electrodes wrapped around the vagus nerve.

Figure No 2: diagram represent pulse generator (reference in  14  )

LEADS (electrode wires)

In a vagus nerve stimulation (VNS) system, the lead wire is the insulated cable that connects the pulse generator (implanted in the chest) to the electrodes wrapped around the vagus nerve in the neck.

It’s a highly specialized medical component made from biocompatible, flexible, and electrically conductive materials, designed to work safely inside the human body for many years.

  • Thin wire that connects the generator to the left vagus nerve in   the neck.
  • Wrapped around the nerve   to deliver   impulses.
  • Connect generator to vagus nerve in the neck. (cuff on nerve)

Components & Materials of a VNS Lead Wire

Part Typical Material Function / Properties

Conductors (core wires) Platinum–Iridium alloy (Pt–Ir) or sometimes MP35N (nickel-cobalt-chromium alloy) Carries electrical pulses from generator to electrodes; excellent conductivity, corrosion resistance, and fatigue strength.

Insulation (outer coating) Silicone elastomer or polyurethane Provides electrical insulation; biocompatible, flexible, and resistant to body fluids.

Electrodes (at nerve end) Platinum–Iridium contacts with silicone cuff Deliver stimulation to the vagus nerve; soft cuff wraps gently around the nerve to avoid damage.

Connector (generator end) Titanium and medical-grade polymer Connects securely to the pulse generator header; ensures a hermetic, low-resistance connection.

Helical (coiled) structure — (Design feature) The wire is coiled like a spring to allow stretching and bending with body movement, minimizing stress and breakage.

  • The platinum–iridium alloy (often 90% Pt / 10% Ir) is the industry standard for implantable leads due to its
  • High conductivity
  • Corrosion resistance
  • Biocompatibility
  • Mechanical strength
  • The silicone insulation ensures flexibility and long-term durability inside soft tissues.
  • The helical (spiral) shape allows the lead to move naturally with neck motion without breaking or damaging the vagus nerve.

DIMENSIONS

  • Lead length: ~43 cm (varies by patient anatomy)
  • Diameter: ~2–3 mm
  • Two or three electrodes at the distal end for stimulation and sensing.

Figure no 3: Diagram represent lead wire of the VNS device (refe =15)

PROGRAMMING SYSTEM: (electrode)

The programming system of a vagus nerve stimulation (VNS) device is the external equipment that allows a clinician to set, adjust, and monitor how the implanted pulse generator delivers electrical stimulation to the vagus nerve.

  • Doctors use a computer and magnetic wand to adjust the strength, duration, and frequency of impulses.
  • External device for doctors to adjust settings. (doctor set signals)

Table No 3: Components of The VNS Programming System

How the Programming Process Works

Patient Visit:

  • The clinician places the wand over the patient’s implant site (usually the upper left chest).
  • The wand communicates wirelessly with the implanted pulse generator.

Device Interrogation:

  • The programmer reads current device settings and diagnostic data (e.g., battery life, lead impedance, stimulation history).

Parameter Adjustment:

  1. The clinician can modify parameters such as:
  2. Output current (mA): strength of the stimulation
  3. Pulse width (μs): duration of each pulse
  4. Frequency (Hz): how many pulses per second
  5. On time / Off time: duration of stimulation and rest cycles
  6. Magnet mode: settings for when a patient uses the external magnet to trigger or stop stimulation
  7. Auto-stimulation: if enabled, adjusts output based on heart rate detection (in models like AspireSR or SenTiva)

Programming Confirmation:

  • New parameters are transmitted to the implant through the wand.
  • The device responds with a confirmation, and the patient’s new stimulation settings take effect immediately.

Example Programming Parameters (Typical Ranges)

Parameter                       Typical Range

Output Current                 0.25 – 3.5 mA

Pulse Width                      130 – 500 µs

Frequency                       20 – 30 Hz

On Time                           30 se

Off Time                          5 min

Figure No 4:Diagram represent programming system of VNS device (refe =16)

Figure No 5: Diagram represents how the doctor adjust the VNS devise frequency as per the patient. (refe =17)

Transcutaneous (Non-Invasive) VNS Devices

These do not require surgery.

They stimulate the vagus nerve through the skin — either at the ear (auricular branch) or the neck.

A. Auricular (Ear-based) VNS

Stimulates the auricular branch of the vagus nerve in the ear.

      1. Examples: NEMOS® (cerbomed / tVNS Technologies, Germany)
          1. Gamma Core Sapphire™ (electro Core, USA – though it targets the neck, not ear)
          2. Parasym™ (UK – for cluster headaches and migraines)
          3. Vitolus, Vagus Fit, etc. (consumer wellness versions)

Figure No 6: image of auricular VNS devise( refe =18)

Figure No 7: Picture of  TAVNS  device ( refe =19)

B. Cervical (Neck-based) tVNS

Stimulates the cervical branch of the vagus nerve through the neck skin.

  Example:

  1. gammaCore™ (electroCore)

FDA-cleared for:

  • Acute migraine treatment
  • Cluster headache prevention and treatment
  • Parxysmal hemicrania and hemicrania continua

Figure No 8: diagram of  NIVNS device (refe =20)

Figure No 9: diagram of CtVNS device (refe =21)

IMPLANTATION PROCEDURE

Before the procedure

Before surgery, you have a physical exam. Your surgeon may have you start taking antibiotics before surgery to prevent infection.

During the procedure

Surgery to implant the vagus nerve stimulation device often is done on an outpatient basis. You go home that day. During surgery, you'll likely get medicine, called general anesthesia, to put you into a sleep like state.

The surgery itself doesn't involve the brain. The surgeon makes two cuts, called incisions. One is on the chest or in the armpit area. The other is on the left side of the neck.

The surgeon puts the pulse generator in the upper left side of the chest. The pulse generator is about the size of a stopwatch. It runs on battery power.

A lead wire connects to the pulse generator. The surgeon guides the lead wire under the skin from the chest up to the neck. Then the surgeon connects the wire to the left vagus nerve through the second cut.

The device and its battery last for years before it needs to be replaced. A surgeon also can remove it, if needed.

After the procedure

If you had the device implanted to treat epilepsy or depression, your healthcare team turns on the pulse generator during a medical visit a few weeks after surgery. Then the team programs how long and how often the device sends electrical impulses to the vagus nerve.

Vagus nerve stimulation most often starts at a low level. Your healthcare team can raise it depending on your symptoms and side effects.

The device turns on and off in cycles, such as 30 seconds on, five minutes off. You may feel some tingling or slight pain in your neck. Your voice may be hoarse when the device is on.

Newer models that treat epilepsy can sense a sudden increase in your heart rate and react by sending a signal to the nerve. A sudden increase in heart rate may mean you're about to have a seizure. You can use a hand-held magnet to start the impulse at other times. For instance, you can turn it on if you feel you're about to have a seizure.

For a device that's put in after a stroke, a specialist most often turns it on during rehabilitation. You also can turn it on at home using a magnet. You might turn it on to help with certain tasks such as cooking.

You need to make follow-up visits to your healthcare professional to make sure that the pulse generator is working and hasn't moved out of place. Check with your healthcare team before having medical tests, such as an MRI. The test might affect the device.

MECHANISIM & WORKING OF VNS

Vagus Nerve Stimulation (VNS) – Mechanism of Action

The vagus nerve stimulation device is a small, battery-powered implant placed under the skin in the chest. It sends mild electrical pulses to the vagus nerve in the neck at regular intervals.

Step-by-step Mechanism:

Electrical pulse generation:

The implanted device (like a pacemaker) produces small, controlled electrical signals.

Signal transmission to vagus nerve:

A thin wire connects the device to the left vagus nerve in the neck. The signals travel through this wire to the nerve.

Activation of brain areas:

The vagus nerve carries the signals to important parts of the brain — such as the thalamus, amygdala, and brainstem — that control mood, seizure activity, and body functions.

Balancing brain chemicals:

The stimulation helps release or regulate neurotransmitters like norepinephrine, serotonin, and GABA, which calm overactive nerve cells.

Reduced abnormal brain activity:

This reduces the irregular electrical activity in the brain that causes epileptic seizures or mood disorders.

Automatic and adjustable:

The device works automatically, but doctors can adjust the strength and timing of the signals using a computer.

Some patients can also trigger extra stimulation using a magnet if they feel a seizure coming.

EXPLANATION

1. Device implantation

  1. A small pulse generator (like a pacemaker) is surgically implanted under the skin of the chest.
  2. A thin wire (lead) runs from the generator to the left vagus nerve in the neck.
  3. The left side is chosen because it has fewer effects on the heart compared to the right side.

2. Electrical pulse generation

  1. The device produces mild, regular electrical impulses at preset intervals.
  2. These impulses are low in intensity and safe for the nerve.

3. Stimulation of the vagus nerve

  1. The electrical pulses travel through the wire and stimulate the vagus nerve fibers.
  2. The vagus nerve acts as a bridge between the body and the brain, carrying signals to the brainstem.

4. Transmission of signals to the brain

Once the vagus nerve is stimulated, the impulses move up to the brainstem, mainly to an area called the nucleus tractus solitarius (NTS).

From there, signals are sent to different regions of the brain such as:

  • Locus coeruleus (controls alertness and norepinephrine release)
  • Thalamus (relay center of the brain)
  • Amygdala and hippocampus (control mood and emotion)
  • Cerebral cortex (controls brain activity)

5. Neurochemical modulation

VNS influences neurotransmitters like:

  • Serotonin (5-HT) – improves mood and reduces depression
  • Norepinephrine (NE) – increases alertness and helps stabilize brain signals
  • GABA – calms overactive neurons
  • This chemical balance reduces abnormal brain firing responsible for epileptic seizures 
  • Signals travel to brain regions controlling seizures, mood, pain.
  • Helps reduce seizures, improve mood, and control inflammation.

TREATMENT

Epilepsy

Anti-seizure medicines don't fully manage seizures for about one-third of people with epilepsy. For some of them, vagus nerve stimulation may help manage their seizures.

The FDA has approved vagus nerve stimulation for people with epilepsy who

  • Are 4 years old and older.
  • Have focal epilepsy. In focal epilepsy, one area of the brain causes the seizures.
  • Can't fully manage their seizures with medicines.
  • Healthcare professionals also may use vagus nerve stimulation for people with generalized epilepsy.

Table No 4: shows VNS device epilepsy trials

Authors

Study/ sample size

Parameters (active group)

Implanted/ transcutaneous

Primary outcome

Study conclusions

Penry and Dean [19]

4 patients with seizure

disorder

PW: 47–50 Hz

On/off: varied

I: 1–3 mA

Implanted

Long-term safety and efficacy

All patients tolerated the procedure with minimal long-term side effects. Seizures were reduced in 3/4 of patients

Uthman et al. [123]

14 patients with medically refractory partial

seizures

PW: 250 μs

Freq: 50 Hz

On/off: 60 s/60 min

I: 1 mA

Implanted

Mean reduction in seizure frequency

Mean reduction in seizure frequency was 46.6% after 14–35 months; 14 of 35 patients showed at least 50% reduction in seizure frequency

Amar et al. [37]

18 patients with

medically refractory

epilepsy and at least

six complex partial or

secondarily generalized

seizures per month

High-level group:

PW: 500μs

Freq: 30 Hz

On/off: 30 s/5 min

I: up to 3.5 mA

Low-level group:

PW:

130μs

Freq: 1 Hz

On/off: 30 s/3 h

I: up to 3.5 mA

Implanted

Comparison of high stimulation VNS vs. low-stimulation on

seizure frequency

High-stimulation VNS patients had significantly greater reduction in seizure frequency at 3- and

18-month follow-up

Scherrmann et al. [38]

 

 

 

95 adult patients with

drug-resistant seizures

who had received

implants

PW: 500 μs

Freq: 20 Hz

On/off: 7 s/30 s

I: 0.25–3 mA

Implanted

Median percentage of reduction in seizure frequency compared to

antiepileptic drug alone

Median percentage of reduction in seizure frequency as compared to baseline was 30%, and seizure outcome was positively correlated with VNS duration

Klinkenberg et al. [40]

41 children with either

partial or generalized

epilepsy

PW: 0.5ms

Freq: 30 Hz

On/off: 30 s/5 min

I: 0.25 mA

Implanted

Comparison of high stimulation VNS vs. low-stimulation on

seizure frequency and severity in children

VNS well tolerated in children, but no significant difference seen in frequency or severity between low and high stimulation groups

Depression

Vagus nerve stimulation may help people with depression. It may be used when medicines, psychological counselling and electroconvulsive therapy haven't worked well.

The FDA has approved vagus nerve stimulation for the treatment of depression in adults who:

  • Have long-lasting, hard-to-treat depression, known as treatment-resistant depression.
  • Haven't improved after trying four or more medicines, electroconvulsive therapy or both.
  • Keep using their other depression treatments with vagus nerve stimulation.

Stroke recovery

For people who are recovering from a stroke, the FDA has approved vagus nerve stimulation for use in rehabilitation. Vagus nerve stimulation with rehabilitation may help people recover the use of their hands and arms after an ischemic stroke.

ONGOING REASCHER ON

  1. Migraine
  2. cluster headache
  3. Rheumatoid arthritis
  4. Crohn’s disease
  5. Heart failure
  6. Anxiety
  7. Obesity

Table No 5: work of VNS as per patient condition

USED TO MANUFACTURE VNS DEVISE

Table No 6: companies  used to manufacture  VNS device

Company names

Devise name/ system

Main use/ Indication

LivaNova plc

VNS Therapy r System

Drug-resistant epilepsy, Depression.

Micro Transponder Inc.

Vivistim Paired VNS system

Stroke rehabilitation (improves arm function)

Setpoint Medical

Bioelectronic VNS system

Autoimmune diseases like rheumatoid arthritis.

BioControl Medical

CardioFit

Heart failure

EnteroMedics

(Reshape lifesciences)

VBLOC Therapy

Obesity treatment

Figure No10: Devices of Different companies.(refe -22)

Side effects

Common side effects of vagus nerve stimulation include:

  • Coughing.
  • Hoarseness.
  • Change in voice.
  • Neck pain or throat pain or tickling.
  • Shortness of breath/trouble breathing (dyspnea).
  • Trouble speaking (dysphonia).
  • Trouble swallowing (dysphagia).
  • Headache.

Advantages of VNS Device

  • Effective in treatment-resistant epilepsy

Reduces frequency and severity of seizures in patients who do not respond to anti-epileptic drugs.

  • Useful for treatment-resistant depression

Provides clinical improvement in mood and depressive symptoms when medications and psychotherapy fail.

  • Non-pharmacological treatment

Avoids long-term drug-related side effects and interactions.

  • Continuous, automatic therapy

Delivers stimulation regularly without requiring patient intervention.

  • Adjustable stimulation parameters

Intensity, frequency, and timing can be optimized based on patient respons

  • Emergency control of seizures

Patients can swipe a magnet over the device to activate extra stimulation during aura or seizure onset.

  • Long-term benefits

Gradual improvement over months and sustained therapeutic response in many patients.

  • Minimal brain invasion

No direct surgery on the brain; device is implanted in the chest with lead attached to vagus nerve.

CONCLUSION

Inevitably, more data will help shape our understanding of how these novel treatments can be made more effective. As in other areas of VNS research, future areas for improvement are in our understanding of how parameters interact with disease state. VNS has an infinite number of parameter combinations, as clinicians can adjust frequency, pulse width, duty cycle, and duration of stimulation. Understanding how these parameter combinations affect treatment outcomes is of utmost importance. Additionally, non invasive VNS has opened the door for further study of the effects of VNS. This includes translation of the wealth of evidence in animal models to human clinical research, as well as further study of how VNS may be an effective treatment for other medical and neuropsychiatric disorders. Discovery of reliable biomarkers will be crucial in aiding the development of personalized VNS treatments, a revolution that is already occurring in other areas of brain stimulation.

In conclusion, the history of VNS spans four decades but has already accomplished a great deal. To date, VNS has gained approvals from the FDA for medication-refractory epilepsy, treatment-resistant depression, obesity, post-stroke motor rehabilitation, and migraine and cluster headache. The development of novel non invasive forms of VNS promises to further advance the field’s evolution.

REFERENCE

  1. https://my.clevelandclinic.org
  2. https://www.mayoclinic.org
  3. https://epilepsysociety.org.uk
  4. LivaNova PLC. VNS Therapy System: for Epilepsy and Depression. Official Website. https://www.livanova.com
  5. BEN-Menachem, E. (2001). Vagus nerve stimulation, current status and clinical application. Acta Neurologica Scandinavica,104(4),1-7. https://doi.org/10.1034/j.1600-0404.2001.00024.x
  6. Cleveland Clinic — “Vagus Nerve Stimulation (VNS): What it is, uses & side effects”
  7. Mayo Clinic — “Vagus nerve stimulation” (implantable & non-invasive)
  8. Johns Hopkins Medicine — explanation of VNS components & uses
  9. Epilepsy Foundation — VNS therapy for seizure control AANS (American Association of Neurological Surgeons) — surgical view & patient info
  10. LivaNova  company info, VNS Therapy for Depression& Epilepsy.
  11. U.S. Food &Drug Administration, us Department of Health &Human Service, Premarket Approval (PMA).
  12. U.S. Food and Drug Administration (FDA). Premarket Approval (PMA)for VNS Therapy System. https://www.accessdia.fda.gov
  13. https://www.researchgate.net/figure/VNS-therapy-modified-from-a-model-proposed_fig1_320464553
  14. https://share.google/BZg2bHH9lz23D0Xew
  15. https://share.google/6Y76mG3F2B3VtdGb8
  16. https://share.google/0vAY5ss504D8xtgYb
  17. https://share.google/rLz5mWyl3xzQodutY
  18. https://share.google/jDodAZAxUzaN385Dq
  19. https://share.google/2at85ddVNPHnaf6Fc
  20. https://share.google/UeOCG0CfxMsK6XAI4
  21. https://share.google/4PqjoV9EiDumVw5Sf
  22. https://share.google/wSVAnDVA6HHrRjNym
  23. Bremner JD et al (2021) Transcutaneous cervical vagal nerve stimulation in patients with posttraumatic stress disorder (PTSD): a pilot study of effects on PTSD symptoms and interleukin-6 response to stress. J Affect Disord Rep. https://d oi.org/1 0 .1016 /j. jadr. 2021. 100190
  24. Austelle CW et al (2023) Transcutaneous auricular vagus nerve stimulation attenuates early increases in heart rate associated with the cold pressor test. Neuromodulation. https:// doi. org/ 10. 1016/j. neurom. 2023. 07. 012
  25. Clancy JA et al (2014) Non-invasive vagus nerve stimulation in healthy humans reduces sympathetic nerve activity. Brain Stimul 7(6):871–877
  26. Antonino D et al (2017) Non-invasive vagus nerve stimulation acutely improves spontaneous cardiac baroreflex sensitivity in healthy young men: a randomized placebo-controlled trial. Brain Stimul 10(5):875–881
  27. Bonaz B, Sinniger V, Pellissier S (2019) Vagus nerve stimulation at the interface of brain-gut interactions. Cold Spring Harb Perspect Med. https:// doi. org/ 10. 1101/ cshpe rspect. a0341 99

Reference

  1. https://my.clevelandclinic.org
  2. https://www.mayoclinic.org
  3. https://epilepsysociety.org.uk
  4. LivaNova PLC. VNS Therapy System: for Epilepsy and Depression. Official Website. https://www.livanova.com
  5. BEN-Menachem, E. (2001). Vagus nerve stimulation, current status and clinical application. Acta Neurologica Scandinavica,104(4),1-7. https://doi.org/10.1034/j.1600-0404.2001.00024.x
  6. Cleveland Clinic — “Vagus Nerve Stimulation (VNS): What it is, uses & side effects”
  7. Mayo Clinic — “Vagus nerve stimulation” (implantable & non-invasive)
  8. Johns Hopkins Medicine — explanation of VNS components & uses
  9. Epilepsy Foundation — VNS therapy for seizure control AANS (American Association of Neurological Surgeons) — surgical view & patient info
  10. LivaNova  company info, VNS Therapy for Depression& Epilepsy.
  11. U.S. Food &Drug Administration, us Department of Health &Human Service, Premarket Approval (PMA).
  12. U.S. Food and Drug Administration (FDA). Premarket Approval (PMA)for VNS Therapy System. https://www.accessdia.fda.gov
  13. https://www.researchgate.net/figure/VNS-therapy-modified-from-a-model-proposed_fig1_320464553
  14. https://share.google/BZg2bHH9lz23D0Xew
  15. https://share.google/6Y76mG3F2B3VtdGb8
  16. https://share.google/0vAY5ss504D8xtgYb
  17. https://share.google/rLz5mWyl3xzQodutY
  18. https://share.google/jDodAZAxUzaN385Dq
  19. https://share.google/2at85ddVNPHnaf6Fc
  20. https://share.google/UeOCG0CfxMsK6XAI4
  21. https://share.google/4PqjoV9EiDumVw5Sf
  22. https://share.google/wSVAnDVA6HHrRjNym
  23. Bremner JD et al (2021) Transcutaneous cervical vagal nerve stimulation in patients with posttraumatic stress disorder (PTSD): a pilot study of effects on PTSD symptoms and interleukin-6 response to stress. J Affect Disord Rep. https://d oi.org/1 0 .1016 /j. jadr. 2021. 100190
  24. Austelle CW et al (2023) Transcutaneous auricular vagus nerve stimulation attenuates early increases in heart rate associated with the cold pressor test. Neuromodulation. https:// doi. org/ 10. 1016/j. neurom. 2023. 07. 012
  25. Clancy JA et al (2014) Non-invasive vagus nerve stimulation in healthy humans reduces sympathetic nerve activity. Brain Stimul 7(6):871–877
  26. Antonino D et al (2017) Non-invasive vagus nerve stimulation acutely improves spontaneous cardiac baroreflex sensitivity in healthy young men: a randomized placebo-controlled trial. Brain Stimul 10(5):875–881
  27. Bonaz B, Sinniger V, Pellissier S (2019) Vagus nerve stimulation at the interface of brain-gut interactions. Cold Spring Harb Perspect Med. https:// doi. org/ 10. 1101/ cshpe rspect. a0341 99

Photo
Spandana Puli
Corresponding author

Assistant Professor, Dr. CSN Institute of Pharmacy.

Photo
Mohana Sri Pujitha Ravada
Co-author

Student, Dr. CSN Institute of Pharmacy.

Photo
Saranya Durga Boppana
Co-author

Student, Dr. CSN Institute of Pharmacy.

Photo
Navitha Busi
Co-author

Student, Dr. CSN Institute of Pharmacy.

Photo
Venkata Durga Inti
Co-author

Student, Dr. CSN Institute of Pharmacy.

Photo
Naveen Gudala
Co-author

Dr. CSN Institute of Pharmacy.

Spandana Puli, Mohana Sri Pujitha Ravada, Saranya Durga Boppana, Navitha Busi, Venkata Durga Inti, Naveen Gudala, Drug Free Implantable Vagus Nerve Stimulation Device (Epilepsy), Int. J. of Pharm. Sci., 2025, Vol 3, Issue 11, 4902-4917. https://doi.org/10.5281/zenodo.17766594

More related articles
Nanosponges as Novel Approach in Drug Delivery Sys...
Pawan Hanute, Suchita Lathi, Rushikesh Thorat, ...
Recent Trends in Stability Indicating Analytical M...
Tulja Raut , Prajakta Maske , Prem Jadhav , Snehal Kadbhane , Anu...
Long-Acting Injectable Drug Systems (LAI) – New ...
Meet Agrawal , Preet Patil, Gagan Patel, Isha Sharma, Upashna Sol...
Assessment Of Incidence & Pattern of Drug Induced Gastrointestinal Disorder in a...
Binu KM, H. Doddayya, Praise Marin Sabbu, Sagnik Ghosh, Nimesh Godwin Johny, Ahmed Bin Md. Batis, Mu...
Stay & Deliver: The Science Behind Gastroretentive Drug Delivery Systems – A R...
Bharathi Mohan, Anbarasu Murugan, Mullaikodi Olivanan, Kannabirran Vaikundam, Rajalingam Dakshinamoo...
Role of Pharmacogenomics in Predicting Adverse Drug Reactions...
Shivani Zodge, Vaishali Bhutambare, Ajay Bhagwat, Ankita Bhapkar, Sajiya Momin, ...
Related Articles
Novel Drug Delivery Systems...
Srushti Koshti, Mayuri Bhosale, ...
Quantum Pathways to Innovation: Redefining the Landscape of Drug Discovery...
Pocham Ravikiran, Mamidala Tejasree, Kethavath Mangulal, Donthula Srilatha, ...
AI in Pharmacovigilance: Transforming Drug Safety Through Digital Innovation...
Gauri Chaudhari, Vaishali Rawal, Sakshi Dawange, Vrushali Ghuge, ...
Review on Nose-To-Brain Drug Delivery...
Umesh Jaybhaye, Shraddha Kayande, Ashwini Waybhase, ...
Nanosponges as Novel Approach in Drug Delivery System...
Pawan Hanute, Suchita Lathi, Rushikesh Thorat, ...
More related articles
Nanosponges as Novel Approach in Drug Delivery System...
Pawan Hanute, Suchita Lathi, Rushikesh Thorat, ...
Recent Trends in Stability Indicating Analytical Method for Drug Substance...
Tulja Raut , Prajakta Maske , Prem Jadhav , Snehal Kadbhane , Anuradha Aghav , ...
Long-Acting Injectable Drug Systems (LAI) – New Generation Therapies...
Meet Agrawal , Preet Patil, Gagan Patel, Isha Sharma, Upashna Solanki , Sahil Patel, Parvez Lakdawal...
Nanosponges as Novel Approach in Drug Delivery System...
Pawan Hanute, Suchita Lathi, Rushikesh Thorat, ...
Recent Trends in Stability Indicating Analytical Method for Drug Substance...
Tulja Raut , Prajakta Maske , Prem Jadhav , Snehal Kadbhane , Anuradha Aghav , ...
Long-Acting Injectable Drug Systems (LAI) – New Generation Therapies...
Meet Agrawal , Preet Patil, Gagan Patel, Isha Sharma, Upashna Solanki , Sahil Patel, Parvez Lakdawal...